316 related articles for article (PubMed ID: 25335885)
1. Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.
Wilson BA; Ho M
Curr Top Med Chem; 2014; 14(18):2081-93. PubMed ID: 25335885
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in botulinum neurotoxin inhibitor development.
Kiris E; Burnett JC; Kane CD; Bavari S
Curr Top Med Chem; 2014; 14(18):2044-61. PubMed ID: 25335887
[TBL] [Abstract][Full Text] [Related]
3. High-throughput screening technologies for botulinum neurotoxins.
Bompiani KM; Dickerson TJ
Curr Top Med Chem; 2014; 14(18):2062-80. PubMed ID: 25335886
[TBL] [Abstract][Full Text] [Related]
4. Strategies to design inhibitors of Clostridium botulinum neurotoxins.
Cai S; Singh BR
Infect Disord Drug Targets; 2007 Mar; 7(1):47-57. PubMed ID: 17346211
[TBL] [Abstract][Full Text] [Related]
5. Challenges in searching for therapeutics against Botulinum Neurotoxins.
Pirazzini M; Rossetto O
Expert Opin Drug Discov; 2017 May; 12(5):497-510. PubMed ID: 28271909
[TBL] [Abstract][Full Text] [Related]
6. 8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.
Dickerson TJ; Smith GR; Pelletier JC; Reitz AB
Curr Top Med Chem; 2014; 14(18):2094-102. PubMed ID: 25335884
[TBL] [Abstract][Full Text] [Related]
7. Current strategies for designing antidotes against botulinum neurotoxins.
Patel K; Cai S; Singh BR
Expert Opin Drug Discov; 2014 Mar; 9(3):319-33. PubMed ID: 24520991
[TBL] [Abstract][Full Text] [Related]
8. A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism.
Simpson LL
Infect Immun; 1986 Jun; 52(3):858-62. PubMed ID: 3011675
[TBL] [Abstract][Full Text] [Related]
9. An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E.
Li M; Lee D; Obi CR; Freeberg JK; Farr-Jones S; Tomic MT
PLoS One; 2018; 13(5):e0197011. PubMed ID: 29746518
[TBL] [Abstract][Full Text] [Related]
10. The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison.
Willis B; Eubanks LM; Dickerson TJ; Janda KD
Angew Chem Int Ed Engl; 2008; 47(44):8360-79. PubMed ID: 18844202
[TBL] [Abstract][Full Text] [Related]
11. Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine.
Machamer JB; Vazquez-Cintron EJ; O'Brien SW; Kelly KE; Altvater AC; Pagarigan KT; Dubee PB; Ondeck CA; McNutt PM
Mol Med; 2022 Jun; 28(1):61. PubMed ID: 35659174
[TBL] [Abstract][Full Text] [Related]
12. Special Delivery: Potential Mechanisms of Botulinum Neurotoxin Uptake and Trafficking within Motor Nerve Terminals.
Winner BM; Bodt SML; McNutt PM
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218099
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.
Derman Y; Selby K; Miethe S; Frenzel A; Liu Y; Rasetti-Escargueil C; Avril A; Pelat T; Urbain R; Fontayne A; Thullier P; Sesardic D; Lindström M; Hust M; Korkeala H
Toxins (Basel); 2016 Sep; 8(9):. PubMed ID: 27626446
[TBL] [Abstract][Full Text] [Related]
14. [Botulism: the agent, mode of action of the botulinum neurotoxins, forms of acquisition, treatment and prevention].
Marvaud JC; Raffestin S; Popoff MR
C R Biol; 2002 Aug; 325(8):863-78; discussion 879-83. PubMed ID: 12391898
[TBL] [Abstract][Full Text] [Related]
15. New targets in the search for preventive and therapeutic agents for botulism.
Anniballi F; Lonati D; Fiore A; Auricchio B; De Medici D; Locatelli CA
Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1075-86. PubMed ID: 25089560
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs.
Barker D; Gillum KT; Niemuth NA; Kodihalli S
PLoS One; 2019; 14(9):e0222670. PubMed ID: 31527885
[TBL] [Abstract][Full Text] [Related]
17. On the mode of action of botulinum toxin.
Leander S; Thesleff S
Acta Physiol Scand; 1980 Feb; 108(2):195-6. PubMed ID: 6246722
[No Abstract] [Full Text] [Related]
18. An improved method for development of toxoid vaccines and antitoxins.
Jones RG; Liu Y; Rigsby P; Sesardic D
J Immunol Methods; 2008 Aug; 337(1):42-8. PubMed ID: 18571196
[TBL] [Abstract][Full Text] [Related]
19. The Janus faces of botulinum neurotoxin: sensational medicine and deadly biological weapon.
Osborne SL; Latham CF; Wen PJ; Cavaignac S; Fanning J; Foran PG; Meunier FA
J Neurosci Res; 2007 May; 85(6):1149-58. PubMed ID: 17387703
[TBL] [Abstract][Full Text] [Related]
20. Clinical recovery and circulating botulinum toxin type F in adult patient.
Sobel J; Dill T; Kirkpatrick CL; Riek L; Luedtke P; Damrow TA
Emerg Infect Dis; 2009 Jun; 15(6):969-71. PubMed ID: 19523306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
